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Introduction
Cytochrome P450 (P450)-catalyzed metabolic activation is highly relevant to respiratory tract injury caused by numerous environmental chemicals, drugs, and other xenobiotic compounds, which enter the body through either the airway or other portals and are present in the systemic circulation. Various P450 enzymes, including members of the CYP2F subfamily, which are preferentially expressed in the respiratory tract, are active toward pulmonary toxicants or procarcinogens (Buckpitt et al., 2002; Hukkanen et al., 2002) . Recombinant CYP2F enzymes, including human CYP2F1, mouse CYP2F2, goat CYP2F3, and rat CYP2F4, have been studied in heterologous expression systems, and one or more of these enzymes have been found to be capable of bioactivating various pulmonary toxicants, including naphthalene (NA), 2-methylnaphthalene, 1-nitronaphthalene, styrene, 3-methylindole, benzene, trichloroethylene, dichloroethylene, and benzo(a)pyrene (see Zhang and Ding, 2008 , for a recent review). However, the relative contribution of CYP2F enzymes to the bioactivation of respiratory tract toxicants remained elusive and merely correlative, due largely to the lack of specific chemical inhibitors or knockout animal models.
NA is the most abundant polycyclic aromatic hydrocarbon (PAH) in ambient urban air (Arey et al 1987) and is released by combustion of wood, gasoline, diesel, and tobacco. The pulmonary toxicity of NA has been studied extensively. NA induced toxicity shows high tissue and species selectivity. It primarily targets Clara cells (nonciliated bronchiolar epithelial cells) lining the airway epithelium of the mouse, causing cytotoxicity after acute exposure via either inhalation or parenteral routes (Plopper et al., 1992; West et al., 2001) . NA treatment also leads to acute cytotoxicity in the nasal mucosa (Plopper et al., 1992) . According to the International JPET #184671 the results of the National Toxicology Program (NTP) chronic rodent bioassays for NA, which found significant, dose-dependent increases in alveolar adenomas in the lungs of female mice, and in adenomas and neuroblastomas of the nasal epithelium in rats (Abdo et al 1992; . The mechanism of NA carcinogenicity is thought to involve repeated cycles of injury and repair related to acute cytotoxicity following bioactivation of NA by P450 enzymes (Brusick 2008 ).
In the lung, the sensitivity of the Clara cells to NA is presumed to be related to efficient metabolic activation catalyzed by CYP2F enzymes localized within these cells (Buckpitt et al., 1995) . Mouse CYP2F2 has high catalytic efficiency toward NA (K m , ~ 3 μ M; Vmax, 104 nmol/min/nmol P450) in vitro (Shultz et al., 1999) . Early in vivo studies in rodents demonstrated a correlation between the covalent binding of reactive NA metabolites and glutathione depletion (Buckpitt and Warren, 1983) . P450 Inhibition decreased, while glutathione depletion increased, covalent binding and toxicity (Warren et al., 1982; Phimister et al., 2004) . However, direct evidence for the role of CYP2F2 in mediating the respiratory tract toxicity of NA has yet to be obtained, and the question is still unresolved whether CYP2F2 is the key enzyme in NA metabolic activation in vivo. The latter question is pertinent, given the fact that several other P450 enzymes expressed in the respiratory tract, including CYP1A, 2A, 2B, 2E, and 3A, are also active in NA bioactivation (Buckpitt et al., 2002; Fukami et al., 2008; Lin et al., 2009) .
In this study, a novel Cyp2f2-null mouse was generated through homologous recombination in embryonic stem (ES) cells derived from the C57BL/6 (B6) mouse strain.
Homozygous Cyp2f2-null mice were characterized for viability and fertility; growth rates; Clara cells distribution and development; and potential compensatory expression of other enzymes that may be involved in NA bioactivation. The Cyp2f2-null mice were compared with wild-type (WT) mice for efficiency of microsomal NA metabolic activation in vitro, as well as rates of systemic JPET #184671
6 NA clearance and extent of NA-induced tissue toxicity in vivo, at NA doses established previously to induce respiratory toxicity in WT mice. The extent of NA-induced lung and OM toxicity was assessed by histological analysis and through measurements of tissue levels of nonprotein Sulfhydryl (NPSH). The results of our studies not only establish the Cyp2f2-null mouse as a valuable model for studies on the role of CYP2F2 in the metabolism and toxicity of numerous xenobiotic compounds, but also provide novel and definitive evidence that CYP2F2
plays an essential role in the bioactivation and toxicity of NA in the lung, but not in the nasal olfactory mucosa (OM).
JPET #184671 8 beginning at ~700-bp upstream of the neo start codon) and external (a 0.9-kbp fragment located ~300-bp upstream of Cyp2f2 exon 2) probes.
ES cells from positive clones were injected into the blastocysts from albino B6(Cg)-Tyr c-2J /J (Jackson Laboratory, Bar Harbor, ME) female mice at the Transgenic and Knockout Core Facility of the Wadsworth Center. Blastocysts were transferred into the uterus of a pseudopregnant B6CBAF1/J mouse, for generation of offspring. Adult male chimeras were bred with B6 female mice, in order to produce germline-transmission F1 mice that were heterozygous for the Cyp2f2-null allele. F2 homozygotes were used for breeding and characterization.
Genotypic analysis of mouse tail DNA for targeted Cyp2f2 allele was performed using the same primers as described above for PCR screening of ES cells. Primers for genotyping WT allele were F2 (5'-agagatgactcggtggctgt-3') and R2 (5'-tttttcccatgccaaagttc-3'). Unless otherwise indicated, B6 mice were used as WT controls in all experiments described. All procedures involving animals were approved by the Institutional Animal Care and Use Committee of the Wadsworth Center.
RNA-PCR analysis of CYP2F2 expression. Total RNA was isolated with use of the RNeasy Mini kit (QIAGEN, Valencia, CA), and was treated with DNase I (Life Technologies, Carlsbad, CA) before reverse transcription (RT). RNA-PCR analysis was performed as previously described (Zhou et al., 2010) , with use of gene-specific PCR primers (5'-gttcagtggccgaggcga-3'and 5'-ggtgagcagacgctcatcgtca-3'; with an annealing temperature of 60°C)
for amplification of a 310-bp fragment corresponding to Cyp2f2 exons 3 through 5. PCR products were analyzed on 1% agarose gels, and visualized by staining with ethidium bromide. A 100-bp DNA marker (Invitrogen, Carlsbad, CA) was used for size determination.
This article has not been copyedited and formatted. The final version may differ from this version. Immunoblot analysis of CYP expression. Immunoblot analysis was carried out essentially as described previously (Ding and Coon, 1990) ; the intensity of the detected bands was quantified through the use of a Bio-Rad GS-710 Imaging Densitometer (Bio-Rad, Hercules, CA). The expression of CYP2A, CYP1A, CYP2B, CYP2E, and CYP3A proteins was analyzed using the following antibodies: rabbit anti-mouse CYP2A5 (Gu et al., 1998) , goat anti-rat CYP1A1/2, goat anti-rat 2B1/2, rabbit anti-rat CYP3A2 (BD Gentest, Woburn, MA), rabbit antirat CYP2E1 (StressGen, Victoria, BC, Canada), and rabbit anti-rat CYP3A (Biomol, Plymouth
Meeting, PA). Expression of CYP2F2 protein was analyzed with a rabbit anti-CYP2F antipeptide antibody (custom-prepared by GenScript, Piscataway, NJ); heterologously expressed human CYP2F1 protein contained in a Sf9 cell microsomal preparation was used as a positive control for immunoblot analysis. Calnexin, a marker protein for the endoplasmic reticulum, was detected using a rabbit anti-human calnexin antibody (GenScript).
Determination of plasma levels of NA and NA-GSH. Mice were given a single intraperitoneal injection of NA (at 300 mg/kg) in corn oil. Blood samples were collected from the tail at various times (15 min to 8 h) after the injection, for preparation of plasma. Tissues from individual mice were homogenized at room temperature, in microsome preparation buffer (0.1 M Tris-acetate buffer, containing 0.15 M KCl and 1.0 mM EDTA, pH 7.4) (Ding and Coon, 1990) , at a w/v ratio of 1 g liver or lung per 3 ml buffer or one pool of dissected OM (~20 mg, from one mouse) in 0.6 ml buffer, using a Polytron (model GT 10-35, Kinematica, Bohemia, NY). acid in methanol). The analytes were eluted, at a flow rate of 0.2 ml/min, using a linear gradient from 10%B to 80%B (between 0 and 8 min), followed by a hold at 80%B for 2 min. The chromatographic condition did not permit baseline-separation of various NA-GSH stereoisomers in the authentic standard; therefore, all stereoisomers were quantitated as a single analyte. The mass spectrometer was set for multiple-reaction monitoring, and was operated in a positive ion mode, with an electrospray ionization source. Nitrogen was used as the curtain gas and the collision gas. The ion-spray voltage was set at 5000 V, the gas temperature at 400 o C, and the declustering and entrance potentials at 50 and 10 V, respectively. The transition ion pair of m/z 452/306 (loss of a hydroxyl and a pyroglutamate group) was used for NA-GSH quantitation, while 452/434 (for the dehydration product) was used for NA-GSH confirmation (Buckpitt et al., 1987) . The collision energy and collision cell exit potential for the m/z 452/306 transition were set to 25 and 10 V, respectively. The transition ion pair for quantitation of the internal standard (AP-GSH) was 457/328 (Bartha et al., 2010) , with the collision energy and collision cell exit potential set as 30 and 10 V, respectively. The retention time for NA-GSH was ~10.18 min, and that for AP-GSH was ~8.90 min. NA-GSH standard (0.05 -20 µg/ml), as well as the internal standard, were added to blank mouse plasma to construct calibration curve. Assays for NA metabolism in vitro. Microsomal metabolic activation of NA was assayed by a determination of the rates of formation of NA-GSH, essentially as described (Shultz et al., 1999) . Reaction mixtures contained 50 mM phosphate buffer, pH 7.4, 2.5~400 µM NA (added in 2 µl methanol), 10 mM GSH, 0.2 mg/ml (for liver and lung), or 0.05 mg/ml (for OM) microsomal protein, and 1mM NADPH, in a final volume of 0.2 ml. The reaction was carried out in sealed tubes at 37 °C for 5 min and quenched by an addition of 2 vol of ice-cold methanol (containing 0.5 ng AP-GSH as internal standard). The resultant mixture was centrifuged to remove precipitated protein, and aliquots of the supernatant were used for NA-GSH This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 5, 2011 as DOI: 10.1124/jpet.111.184671
at ASPET Journals on November 5, 2017
jpet.aspetjournals.org Downloaded from determination, as described above. In control incubations, the reaction was quenched prior to the addition of NADPH.
Histopathological examination. Tissues were fixed in 10% neutral buffered formalin (for liver and lung) or in Bouin's solution (for nose) and then sectioned and stained with hematoxylin and eosin (H&E) for pathological examination, as described before (Gu et al., 2003; 2005) . For in-depth histological analysis of the extent of lung toxicity, the lungs were pressure perfused with Karnovsky's fixative (Tousimis, Rockville, MD) at 30 cm for 1 h by intra-tracheal instillation, immersed in Karnovsky's fixative, embedded in epoxy resin (Araldite 502, Electron
Microscopy Sciences, Hatfield PA), sectioned at 1 µm, and stained with methylene blue/Azure II (Plopper et al., 1992) .
Immunohistochemical analysis of Clara cell secretory protein (CCSP) expression.
Immunohistochemical analysis of CCSP expression was conducted as described previously (Weng et al., 2007) . The lungs were fixed in 10% formalin and embedded in paraffin. After deparaffinization and dehydration, tissue sections were subjected to antigen retrieval in citrate liver, lung, and OM were determined as described (Tonge et al., 1998; Xie et al., 2010) , with use of GSH as a standard. Lung, liver, and OM microsomes were prepared as described previously (Gu et al., 1997) . Pharmacokinetic parameters were calculated using the WinNonlin software (Pharsight, Mountain View, CA). Enzyme kinetic parameters were calculated using GraphPad Prism v.5 (GraphPad Software, San Diego, CA). Statistical significance of differences between two groups in various parameters was examined using Student's t-test.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Generation and characterization of the Cyp2f2-null mouse. The structures of the WT Cyp2f2 allele, the targeting construct, and the Cyp2f2-null allele are shown in Figure 1A . The targeting vector contained, sequentially, a 1.7-kb 5'-homology region corresponding to exons 2 and 3, the neomycin-resistance gene (neo) cassette in reverse direction, a loxP site, and an 8.0-kb 3'-homology region containing exons 5-9. In the Cyp2f2-null allele, the Cyp2f2 exon 4 (coding exon 3) was replaced by neo, through homologous recombination in ES cells derived from the B6 strain. Two positive clones (#30 and #43) were selected for blastocyst injection; they did not contain random insertion of the targeting construct, as indicated by Southern blot analysis with both internal and external DNA probes (data not shown). Ten male chimeras were identified, three of which exhibited germline transmission after crossbreeding with WT B6 female mice.
The germline-transmission F1 heterozygotes were then intercrossed to generate F2 homozygous Cyp2f2-null (Cyp2f2 -/-) mice. Genotypes were confirmed by the presence of the characteristic bands for the WT (6.5-kb) and the Cyp2f2-null (11.6-kb) alleles on Southern blots (Fig. 1B) .
Absence of CYP2F2 mRNA and protein expression in the lungs of the null mice was confirmed by PCR and immunoblot analysis, respectively (Fig. 1C ).
Homozygous Cyp2f2-null mice were fertile, and normal in general appearance, and daily activities. Genotype frequency (number of pups with a given genotype/total number of pups born) among the pups derived from intercrosses between Cyp2f2 +/-mice was 25% (28/112) for lung, brain, testis, and heart for males, and liver, kidney, lung, brain, and heart for females) were similar between Cyp2f2-null and WT B6 mice (Supplemental Table 1 ), indicating normal growth.
Additionally, liver, lung, and OM microsomal levels of several P450 proteins, including CYP1A, CYP2A, CYP2B, CYP2E, and CYP3A, were similar between Cyp2f2-null and WT mice, signifying absence of compensatory increases in the expression of these other Cyp genes in the Cyp2f2-null mice (Supplemental Figure 1) . Furthermore, the expression of CCSP, a developmental marker within the bronchiolar epithelium (Hackett and Gitlin, 1992) , in various lung regions, including distal and mid-level airways and terminal bronchiolar, was found to be indistinguishable between Cyp2f2-null and WT mice (Supplemental Figure 2) , indicating absence of any obvious defects in lung development in the Cyp2f2-null mice.
Role of CYP2F2 in microsomal NA metabolic activation in vitro. The rates of NA-
GSH formation in incubations with lung, liver, or OM microsomes were compared between
Cyp2f2-null and WT mice, with NA used at a broad range of concentrations. Typical HPLC chromatogram, MS/MS spectrum, and calibration curve used for quantitation of NA-GSH are shown in Supplemental Data (Supplemental Figure 3) . Enzyme kinetic constants, estimated by nonlinear regression to Michaelis-Menten equation for either one-or two-component enzyme kinetics, as illustrated in a previous study (Siu and Tyndale, 2007) , are shown in Table 1 . The kinetic data are also shown as substrate-velocity curves (Supplemental Figure 4) . The involvement of more than one enzymatic component for lung and OM microsomes from WT mice was confirmed by the Eadie-Hofstee method (Fig. 2) between the Cyp2f2-null and WT groups. These findings indicated that CYP2F2 is the major enzyme involved in NA bioactivation in the lung, at both high and low NA concentrations. In the liver and OM, CYP2F2 also contributed significantly to microsomal metabolism of NA, although the extent of CYP2F2's contribution were much less than in the lung, and became almost insignificant at high NA concentrations.
Role of CYP2F2 in NA metabolism in vivo. Pharmacokinetics of NA clearance was compared between Cyp2f2-null and WT mice, with NA administered at 300 mg/kg (i.p.). Plasma NA reached maximal concentration at ~30 min after injection, and then decreased quickly in both Cyp2f2-null and WT mice (Fig. 3A) . In the Cyp2f2-null mice, NA clearance (as indicated by CL/F value) was significantly decreased, accompanied by 2.8-fold and 3.4-fold increases in C max and AUC values, respectively ( Table 2 ). The formation of the GSH-trapped metabolite NA-GSH was also determined in both groups (Fig. 3B) . Consistent with decreases in NA metabolism, the plasma levels of NA-GSH were substantially lower in the Cyp2f2-null than in WT mice, as indicated by 3.0-fold and 3.1-fold decreases in the C max and AUC values, respectively (Table 2) .
These results show that CYP2F2 plays an important, although not absolute, role in NA clearance.
Given that CYP2F2 is expressed in both liver and the lung, we next assessed the relative contributions of lung and liver CYP2F2 to NA systemic metabolism, by comparing NA metabolism between LCN mice (which have little microsomal P450 activity in the liver) and their WT littermates. We found that plasma NA levels were much higher in LCN than in WT mice, treated with NA at 300 mg/kg ( Fig. 3C ; (presumably CYP2F2)-dependent NA metabolism is essential for the first-pass metabolism of intraperitoneally injected NA. Interestingly, the loss of hepatic P450 activity did not reduce the C max or AUC for plasma levels of NA-GSH ( Fig. 3D ; Table 2 ), although the T max appeared to be slightly increased. This latter result, which can be explained partly by the increased bioavailability of NA in the LCN mice, confirms that P450 enzymes in extrahepatic tissues (most probably the lung, where CYP2F2 is most abundant) are fully capable of producing reactive NA epoxides in vivo.
Role of CYP2F2 in the NA-induced tissue toxicity. NA is known to induce respiratory tract toxicities, including observable lesions in the lung and OM, irrespective of the route of administration (Buckpitt et al., 2002) . To determine the role of CYP2F2 in NA toxicity in vivo,
we compared the extent of tissue toxicity in WT and Cyp2f2-null mice (Table 3 and Tissue NPSH levels, as an early marker of cytotoxicity (Phimister et al., 2004) , were also determined for WT and Cyp2f2-null mice, at 2 h following NA dosing at 300 mg/kg (Table 4) .
Corn oil was used as vehicle control. Consistent with the results of pathological examination at 24 h following NA treatment, there was no significant decrease in lung NPSH levels in NAtreated, compared with vehicle-treated, Cyp2f2-null mice, at 2 h after NA dosing; whereas a 40% decrease in lung NPSH levels was found in NA-treated WT mice. For the OM, NPSH levels decreased by ~85% in both mouse strains, following NA treatment, compared with vehicle controls, confirming the earlier conclusion from the histopathological data that CYP2F2 does not play a significant role in NA-induced nasal toxicity at the doses studied. For the liver, NPSH levels decreased by ~83% in WT mice, and ~70% in Cyp2f2-null mice, following NA treatment, compared with corresponding vehicle-treated mice, consistent with a relatively minor role of CYP2F2 in hepatic NA metabolic activation.
Tissue levels of NA and NA-GSH were also determined in lung, liver, and OM, at 2 h after NA treatment (Table 5) . Consistent with the NPSH data, the loss of CYP2F2 was associated with a 77% decrease in NA-GSH levels and 70% increase in NA level (compared with WT mice) in the lung; but it had only marginal effects on liver NA-GSH or NA levels, and had essentially no effects on NA-GSH or NA levels in the OM. Taken together, these results indicate that lung CYP2F2 plays the most important role in NA metabolic activation in the lung and in NA- . As with Cyp2a5-null and Cyp2g1-null models, the Cyp2f2-null mouse was generated on a B6 genetic background. Homozygous Cyp2f2-null mice were fertile and had no discernible difference from WT mice in body weights, growth rates and major organ weights; these phenotypes were not unexpected given the fact that there has been no endogenous substrate identified for any of the CYP2F enzymes, and they also affirm that the insertion of neo in place of the Cyp2f2 4 th exon did not cause any adverse effect on development, reproduction, or growth. The presence of neo (and the loss of CYP2F2) did not seem to affect the expression of neighboring Cyp2a or Cyp2b genes or that of several other Cyp genes examined, in contrast to the neighboring effect seen previously in the Cyp2g1-null/Cyp2a5-low model (Zhuo et al., 2004) .
In that regard, Cyp2f2 is flanked by two Cyp pseudogenes: Cyp2a20-ps on the 5' side and Cyp2t4 on the 3' side (Wang et al., 2003) , which might have served to insulate any effects of the neo transcription on more peripheral genes.
Our finding that NA-induced lung injury is essentially abolished in the Cyp2f2-null mouse confirms the long-held suspicion that CYP2F2 plays a critical role in the high sensitivity of mouse lung to NA toxicity (Buckpitt et al., 2002; Cruzan et al., 2009 ). Our finding that NA toxicity in the OM was essentially unaffected by the loss of CYP2F2 is also interesting, as it illustrates the complexity of the metabolic mechanisms underlying site selective respiratory tract toxicity of xenobiotic compounds. The tissue difference in the impact of CYP2F2 loss on NAThis article has not been copyedited and formatted. The final version may differ from this version. It is well recognized that NA induces respiratory tract cytotoxicity in rodents irrespective of the route of administration (Plopper et al., 1992; West et al., 2001 ). In the present study, the intraperitoneal route was used according to assay conditions previously established for testing acute respiratory tract toxicity in mice (Plopper et al., 1992) . It is conceivable that the Cyp2f2-null mouse will be likewise resistant to NA-induced lung toxicity in other exposure models, as the routes of exposure will only change the internal dose available for bioactivation, but not the presence of the highly abundant CYP2F2 in the lungs for target tissue NA metabolic activation.
CYP2F2 is expressed in the mouse liver, as well as in the respiratory tract, with the concentration of CYP2F2 protein being comparable in liver and lung microsomes. Our finding that clearance of intraperitoneally injected NA was significantly decreased in both the Cyp2f2- given the location of the lung at the portal of entry; the extent of CYP2F2's contribution in that regard remains to be determined experimentally. Notably, NA absorption and systemic distribution are expected to be rapid, and thus hepatic contribution to systemic clearance of inhaled NA is also likely.
Interestingly, whereas the decrease in NA clearance in the Cyp2f2-null mouse was accompanied by a comparable decrease in the levels of NA-GSH, a marker for reactive NA metabolites produced in vivo, the decreased NA clearance in the LCN mouse was not accompanied by a corresponding decrease in plasma NA-GSH. This data support the idea that lung CYP2F2 is sufficient for mediating NA metabolic activation and lung toxicity, and that it also contributes to systemic formation of NA-GSH. However, it remains to be determined whether liver-generated reactive NA metabolites contribute to NA-induced lung or nasal toxicity in WT mice.
The Cyp2f2-null mouse model will likely have broad applications for studying the toxicity of other chemicals that are CYP2F substrates. In addition to NA, CYP2F enzymes also metabolize numerous other lung toxicants, such as 3-methylindole, styrene, and trichloroethylene (cf. Zhang and Ding, 2008) , for which human risks of lung toxicity remain unclear. In that regard, preliminary studies on styrene toxicity in the Cyp2f2-null mice have been reported indicating that CYP2F2 also plays a critical role in the lung toxicity of styrene in mice (Cruzan et al., 2011) .
The demonstration of a critical role of CYP2F2 in NA-induced lung toxicity in mice begs the question of whether the human ortholog, CYP2F1, is also important for NA metabolic activation in humans. However, although both human lung and human liver can metabolize NA (Buckpitt and Bahnson 1986; Cho et al 2006) , the role of human CYP2F1 in NA bioactivation is not well understood, due in large part to repeated failures in multiple laboratories to produce Although our data is conclusive in demonstrating the important role of CYP2F2 in NAinduced lung toxicity, it remains to be determined whether, under certain conditions, NA metabolism by mouse CYPs other than CYP2F2 can mediate NA toxicity in Cyp2f2-null lungs, which may serve as a model for human lungs with little CYP2F1 expression or activity, but express other P450 enzymes, such as CYP1A1 (van Bladeren et al., 1985) and CYP2A13 (Fukami et al., 2008) , that are capable of bioactivating NA. The conditions that may enhance the participation of the less efficient P450 enzymes in NA bioactivation in vivo include higher NA doses, which may occur when NA exposure is through inhalation or dermal absorption (thus bypassing first-pass metabolism by the digestive organs), and a higher expression level of the P450 enzymes, due to site-specific enrichment in select lung regions, as previously demonstrated (Buckpitt et al., 1995) . Additionally, NA toxicity was only examined at 24 h after dosing in the present study. Lung toxicity might be detected in the Cyp2f2-null mice at a later time.
In summary, a novel Cyp2f2-null mouse model was generated and characterized in this study. The mouse model has been found to be ideal for determination of the roles of CYP2F2 in Contents of reaction mixtures are described in Materials and Methods. Microsomes were prepared from pooled OM, lungs, or livers from five male, 2-month-old mice. The rates of NA-GSH formation were determined at various NA concentrations (2.5 to 400 µM). The data (means ± S.D., n = 3) were curve-fitted to the Michaelis-Menten equation. Substrate-velocity curves for the same kinetic data are shown in Supplemental Data (Supplemental Figure 4) . The calculated apparent kinetic parameters are shown in Table 1 . 
